Phase 3 Clinical Trials With Primary Completion Dates in March 2021

This is a list of Phase 3 trials with primary completion dates in March 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AGLE Aeglea BioTherapeutics, Inc. 2021-03-01 Phase 3 NCT03921541 Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency
ARQT Arcutis Biotherapeutics, Inc. 2021-03-01 Phase 3 NCT04286607 Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
HGEN Humanigen, Inc. 2021-03-01 Phase 3 NCT04351152 Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
MMSI Merit Medical Systems, Inc. 2021-03-01 Phase 3 NCT01387932 HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
NEPH Nephros, Inc. 2021-03-01 Phase 3 NCT03534284 Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
RIGL Rigel Pharmaceuticals, Inc. 2021-03-01 Phase 3 NCT03764618 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
SYNH Syneos Health, Inc. 2021-03-01 Phase 3 NCT04541004 Adolescent Mite Allergy Safety Evaluation